Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 135, Issue 3, Pages 731-741
Publisher
Wiley
Online
2013-12-26
DOI
10.1002/ijc.28698
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
- (2013) J M Jürgensmeier et al. BRITISH JOURNAL OF CANCER
- Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
- (2013) M. Peeters et al. CLINICAL CANCER RESEARCH
- Predictive Biomarkers for Bevacizumab: Are We There Yet?
- (2013) D. Maru et al. CLINICAL CANCER RESEARCH
- Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma
- (2013) Rekha Gyanchandani et al. ORAL ONCOLOGY
- Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab
- (2013) Timothy J. Price et al. Cancer Medicine
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
- (2012) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiangiogenic therapy—evolving view based on clinical trial results
- (2012) Gordon C. Jayson et al. Nature Reviews Clinical Oncology
- Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas
- (2011) Qingguo Li et al. BMC CANCER
- RNA Interference-Mediated Vascular Endothelial Growth Factor-C Reduction Suppresses Malignant Progression and Enhances Mitomycin C Sensitivity of Bladder Cancer T24 Cells
- (2011) Hui-hui Zhang et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Impact ofKRASandBRAFGene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
- (2011) Timothy J. Price et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C
- (2010) Avanti Verma et al. BJU INTERNATIONAL
- Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer
- (2010) Kyung A Kwon et al. BMC CANCER
- Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
- (2010) Amir Abdollahi et al. DRUG RESISTANCE UPDATES
- Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells
- (2010) Antonella De Luca et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
- (2010) Niall C. Tebbutt et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer
- (2010) Jian-fang Liang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Pathways mediating VEGF-independent tumor angiogenesis
- (2009) Napoleone Ferrara CYTOKINE & GROWTH FACTOR REVIEWS
- EDTA plasma is unsuitable for in vivo determinations of platelet-derived angiogenic cytokines
- (2009) Robert Zimmermann et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Biomarkers of response and resistance to antiangiogenic therapy
- (2009) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- Generation of high-quality protein extracts from formalin-fixed, paraffin-embedded tissues
- (2009) Maria Filippa Addis et al. PROTEOMICS
- Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells
- (2008) F. Shojaei et al. CANCER RESEARCH
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Significance of VEGF Expression Evaluated by Quantitative Immunohistochemical Analysis in Colorectal Cancer
- (2007) Kyriakos Zafirellis et al. JOURNAL OF SURGICAL RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now